News

DRYWORLD's Ambitious Move into Soccer Kit Supply Sector

DRYWORLD's Ambitious Move into Soccer Kit Supply Sector

DRYWORLD's Strategic Initiative in Soccer Apparel

DRYWORLD Brands Inc. (OTC: IBGR) is excited to announce its focused initiative aimed at tapping into the lucrative market of top-tier soccer kit supplies, particularly within the UK and Europe. As a leading name in sportswear and performance branding, this move represents a significant opportunity for growth and further global expansion.

The Soccer Kit Supply Market

Globally, the soccer kit supply market is a multi-billion-dollar industry. The vibrant leagues operating in the UK and Europe are central to this market, hosting passionate fanbases that span the globe. By securing high-profile kit supply deals, DRYWORLD has the potential to establish a robust revenue stream that lasts for years, alongside solidifying its reputation in the competitive arena of sports apparel. Collaborating with top clubs could enhance brand visibility and create numerous possibilities for sponsorships and merchandise sales, fostering a deeper sense of loyalty among customers worldwide.

Quotes from Leadership

Brian McKenzie, Co-CEO of DRYWORLD, expressed excitement about this initiative: "This strategic decision aligns with our long-term vision of global expansion and revenue diversification. The reach of soccer’s top leagues will amplify our presence, connecting us with millions of fans and driving substantial growth in our business. We’re looking forward to seeing our brand on the field with the world’s best teams."

Matt Weingart, Co-CEO alongside McKenzie, added: "Soccer is a sport with unmatched global reach, and entering this market represents an exciting new chapter for DRYWORLD. We believe our innovative approach to performance-driven sportswear, combined with our commitment to sustainability and fan engagement, will make a meaningful impact in the soccer world. This is a pivotal moment for us as we expand our brand into a market that is passionate, dynamic, and growing."

About DRYWORLD

DRYWORLD is a forward-thinking performance sports brand dedicated to offering high-quality apparel and gear designed for athletes at every level. Our mission focuses on creating purpose-driven products that empower athletes, engineered with precision and proven through rigorous scientific testing. Explore our offerings at dryworldshop.com.

Frequently Asked Questions

What is DRYWORLD's new initiative?

DRYWORLD is focusing on entering the soccer kit supply market in the UK and Europe, aiming to partner with top-level soccer clubs.

Why is the soccer kit market important for DRYWORLD?

The soccer kit supply market offers significant growth potential with recurring revenue and branding opportunities, enhancing their global presence.

How does DRYWORLD plan to engage with soccer clubs?

By pursuing partnerships with clubs that match their values of performance, innovation, and sustainability, they aim to create meaningful connections.

Who are the key leaders in this initiative?

Brian McKenzie and Matt Weingart, both Co-CEOs of DRYWORLD, are leading this initiative, emphasizing the importance of global reach.

What sets DRYWORLD apart in the sportswear industry?

DRYWORLD focuses on performance-driven sportswear designed through an athlete-centric approach, combining innovative design with sustainability.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Johnson & Johnson's JNJ-6143 Shines in Prostate Cancer Study

Updated Category News Views 145

Prostate Cancer's Persistent Challenge No one in the healthcare game needs the reminder: prostate cancer is no walk in the park, especially for those grappling with advanced stages. Now picture this—you're on your sixth treatment, and the cloud is not lifting. It's a battle that never ends, with traditional therapies sometimes barely holding the line. JNJ-6143's New...

Continue Reading
Love Business Group Helps SMEs Navigate Broadband Choices

Updated Category News Views 17

Understanding Broadband Needs for UK SMEs When you're knee-deep in running a small biz in the UK, sorting out your broadband needs can feel like sifting through a thousand-piece puzzle. Enter Love Business Group, getting a nod of recognition for being the SME knight in shining armor. Aimed at businesses of all sizes, they've been pegged by Expert Consumers for helping...

Continue Reading
Sac-TMT's Phase III Success Shifts Lung Cancer Paradigm

Updated Category News Views 311

A New Era in Lung Cancer Treatment? Sac-TMT, the novel antibody-drug conjugate (ADC), just might be shaking up the non-small cell lung cancer (NSCLC) treatment landscape, and boy, is it making waves. Just when you think you’ve seen it all, here comes sacituzumab tirumotecan (sac-TMT), offering a glimmer of hope for patients whose treatment options have dwindled after...

Continue Reading
ASTS Faces Crucial Deadline Amidst Legal Turmoil

Updated Category News Views 208

Ah, the ticking clock in the world of stock investments, where a nifty little thing called a class action lawsuit can flip your investment on its head. Right now, AST SpaceMobile (NASDAQ: ASTS) investors are staring down the barrel of one such lawsuit. With the November 13, 2026, deadline looming, it's time to sort the facts from the muck. Pins and Needles for ASTS...

Continue Reading
RYBREVANT's Promising Results in HNSCC Treatment

Updated Category News Views 35

Impressive Outcomes for RYBREVANT FASPRO in Head and Neck Cancer Tucked away in the endless cycle of drug trials, a glimmer of hope shines through with new data on RYBREVANT FASPRO in treating head and neck squamous cell carcinoma (HNSCC). This science talk might not rattle the ticker tape directly on NYSE:JNJ, but it has all the makings of a game-changer in the oncology...

Continue Reading
Firefox Champions Privacy with Iconic Internet Campaign

Updated Category News Views 68

Rekindling the Internet’s Golden Days with Firefox There’s something almost poetic about Firefox hustling to win back its old users by launching a campaign with legendary internet icons. The backdrop? A digital landscape where privacy feels about as common as a unicorn sighting. Mozilla's pulling a major nostalgia card, and I'm here for it—sort of like how vinyl...

Continue Reading
Innovent's IBI354: New Data Spurs Hope for HER2+ BC

Updated Category News Views 106

Innovent Lauds HER2 ADC's Moment at ESMO 2026 Alright, chin up, investors. At the 2026 ESMO Congress, Innovent's throwing down some promising Phase 2 data for their brainchild, IBI354. You hear that name and it's like hearing about a rock star in the making in the oncology world. The potential here isn’t just talk—it's a loud, resounding call for attention. Their...

Continue Reading
Kelun-Biotech's Sacituzumab Tirumotecan Shows Promise in NSCLC

Updated Category News Views 147

Kelun-Biotech's Recent Breakthrough Grab your coffee, and let's chat about something that might just change the lung cancer treatment game: Kelun-Biotech's sacituzumab tirumotecan, or sac-TMT, showing some serious promise in a Phase III trial. With numbers that could make any investor sit up a little straighter, this study has turned heads at the European Society for...

Continue Reading
Gildan Activewear Faces Legal Battle Over Alleged Fraud

Updated Category News Views 0

Investor Alert: Gildan's Legal Showdown Alright, here's a twist you didn't see coming—or maybe you did if you've been tracking the ticker tapes like a hawk. Gildan Activewear Inc. (NYSE:GIL) is stuck in the kind of hot water that can scald the bottom line. The Stakes: Racing Towards December 14 Marked on your calendar, December 14, is a date of some significance if...

Continue Reading
TORRAS Cases Balance Protection with Slim Design for 2026

Updated Category News Views 113

Are Slim iPhone Cases Really Protecting Your Investment? Anyone who's dropped a brand-new phone knows the pain of watching your investment smack the concrete. But hey, welcome to 2026, where Consumer365's latest rundown on iPhone protective gear turns the spotlight on TORRAS. These folks grabbed attention with their Q3 Air and Q3 Air Pro cases, crafted for iPhone 18 Pro...

Continue Reading

Top 5 Most Recently Viewed Articles

Regeneron Faces Class Action Over Tumultuous Trial Results

Updated Category News Views 13

Regeneron's Meltdown: A Bitter Pill for Investors Let’s dive headlong into the mess Regeneron Pharmaceuticals (NASDAQ:REGN) finds itself in—a classic nightmare scenario for investors. News broke like an old valve bursting, and suddenly, the market's love for Regeneron ran ice-cold. Who's to blame this time? Well, you might want to point a finger at the failed Phase 3...

Continue Reading
Avalo Therapeutics Achieves Significant Milestones in 2025

Updated Category News Views 332

Avalo Therapeutics: Progress and Financial Highlights Avalo Therapeutics, Inc. (NASDAQ: AVTX), a dedicated biotechnology company, focuses on developing innovative therapies targeting immune-mediated inflammatory diseases. Recently, Avalo announced significant updates and financial results for the second quarter of 2025, showcasing a robust pipeline and strong financial...

Continue Reading
Splash Beverage Group Shares Surge: Insights on Recent Growth

Updated Category News Views 155

Splash Beverage Group Inc. Sees Major Stock Surge Recently, shares of Splash Beverage Group Inc. (NASDAQ: SBEV) soared by an impressive 40.52% during after-hours trading. The stock reached a price of $1.05, marking a significant rebound from previous lows. Understanding the Price Movement During regular trading hours, SBEV shares had closed at $0.75, reflecting a decrease...

Continue Reading
Streamlining ACA Form Corrections with ez1095 Software

Updated Category News Views 118

Revolutionizing ACA Compliance with ez1095 For current clients using ez1095, navigating the complexities of ACA form corrections has become profoundly easier. Already in use for 2024, the ez1095 software revolutionizes the way clients manage their forms, eliminating the headaches traditionally associated with such tasks. Enhancements and Features of ez1095 The ez1095 team...

Continue Reading
Roth Staffing Companies Celebrates Recognition as Top Workplace

Updated Category News Views 231

Roth Staffing Companies Earns Top Workplace Honor for 2025 Roth Staffing Companies is thrilled to announce that it has received the prestigious Top Workplaces USA award for 2025. This honor, given by a renowned organization, celebrates companies that prioritize a positive work culture and engage their employees effectively. Celebrating Company Culture The Top Workplaces...

Continue Reading